Arthur Tzianabos, Ph.D., brings 25 years of experience in the biotechnology industry leading teams in the discovery, development, clinical translation and commercialization of new treatments for rare diseases. During his nine-year tenure at Shire, he played an active role in the development, approval, and commercial launch of multiple therapies for patients with rare genetic disorders. He also worked closely with the Business Development and Corporate Venture functions to invest in and acquire new companies and technologies to build Shire’s product pipeline. Dr. Tzianabos joins Homology Medicines from OvaScience where he served as President and CSO and was responsible for translating breakthrough science into new treatments, which included the commercial launch of the company’s first product. Earlier in his career, Dr. Tzianabos was an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. He has published more than 80 scientific papers, reviews, book chapters, and patents. He is a member of the Board of Directors for Akouos, Stoke Therapeutics and the Alliance for Regenerative Medicine, and he serves on the Development Board for the University of New Hampshire’s College of Life Sciences and Agriculture. Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire.